<DOC>
	<DOCNO>NCT01554410</DOCNO>
	<brief_summary>The primary objective study identify high dose gemcitabine give safely cisplatin pelvic intensity modulate radiation therapy ( IMRT ) woman locally advanced cervical cancer . The investigator hypothesis IMRT reduce gastrointestinal hematologic toxicity , permit escalate dos gemcitabine feasibly deliver patient locally advanced cervical cancer .</brief_summary>
	<brief_title>Intensity Modulated Radiation Therapy With Cisplatin Gemcitabine Treat Locally Advanced Cervical Carcinoma</brief_title>
	<detailed_description>Many study investigate multiagent chemotherapy mean intensifying treatment . The result trial indicate gemcitabine considerable activity cervical cancer give cisplatin/RT , however , quite toxic . The predominant toxicity gastrointestinal hematologic . Methods reduce gastrointestinal hematologic toxicity chemoradiotherapy could mitigate toxicity take advantage therapeutic benefit gemcitabine IMRT advance radiation therapy delivery technique reduces amount radiation give normal tissue may therefore reduce unwanted side effect . IMRT try low amount radiation normal tissue receive , still deliver desired amount radiation cancer cell area , lymph node . IMRT use computer design best way aim radiation tumor ( ) , still deliver radiation dose comparable standard radiation .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Diagnosis : Histologicallyproven , invasive primary carcinoma cervix . Disease Status : Stage IB2IVA cervical cancer stage I biopsyproven pelvic node metastasis , positive surgical margin , parametrial extension base upon standard diagnostic workup , include : History/physical examination Examination anesthesia ( indicate ) Biopsy Intravenous pyelogram and/or cystoscopy ( indicate ) Colonoscopy , sigmoidoscopy , rigid proctoscopy ( indicate ) PA lateral chest xray chest CT CT MRI pelvis PET , PET/CT , PET/CT simulation ( encourage ) Performance Level : Karnofsky Performance Status ≥ 60 Peripheral ≥ ANC 1500/uL Platelet count ≥ 100,000/uL ( transfusion independent ) Hemoglobin ≥ 8.0 g/dL ( Note : The use transfusion intervention achieve Hgb ≥ 8.0 g/dL acceptable ) Serum creatinine ≤ 1.5 mg/dl Bilirubin ( sum conjugate + unconjugated ) &lt; 1.5 mg/dl , SGPT ( ALT ) &lt; 1.5 x upper limit normal ( ULN ) age , SGOT ( AST ) &lt; 1.5 x upper limit normal ( ULN ) age Pregnancy BreastFeeding : Pregnant breastfeed woman enter study due risk fetal teratogenic adverse event . ( Note : Serum Pregnancy test must obtain woman child bear potential ) . Sexually active female may participate unless agree use effective contraceptive method ( abstinence , diaphragm , condom , intrauterine device ) prevent pregnancy duration study . Concomitant Medications , take within last 28 day . Growth factor ( ) : Growth factor support platelet white cell number function must administer within past 28 day . Erythropoietic drug ( ) : Erythropoietin related hormone must administer within past 28 day . Infection : Patients uncontrolled infection . Evidence paraaortic lymphadenopathy distant metastases Prior invasive malignancy ( except nonmelanomatous skin cancer ) , unless disease free minimum 3 year . Prior systemic chemotherapy within last three year . Prior radiotherapy pelvis Allergic iodinate contrast undergoing contrast enhance CT scan pelvis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Cervical</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>IMRT</keyword>
	<keyword>Radiation</keyword>
	<keyword>External Beam</keyword>
	<keyword>Brachytherapy</keyword>
</DOC>